{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:41:51Z","timestamp":1783352511677,"version":"3.54.6"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Limited real-world data exists on clinical outcomes in systemic lupus erythematosus (SLE) patients by SLE Disease Activity Index 2000 (SLEDAI-2\u00a0K), hereafter, SLEDAI. We aimed to examine the association between SLEDAI score and clinical, patient-reported and economic outcomes in patients with SLE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Rheumatologists from the United States of America and Europe provided real-world demographic, clinical, and healthcare resource utilization (HCRU) data for SLE patients. Patients provided self-reported outcome data, capturing their general health status using the EuroQol 5-dimension 3-level questionnaire (EQ-5D-3\u00a0L), health-related quality of life using the Functional Assessment of Chronic Illness Therapy (FACIT) and work productivity using the Work Productivity and Activity Impairment questionnaire (WPAI). Low disease activity was defined as SLEDAI score\u2009\u2264\u20094 and \u2264\u20097.5\u00a0mg\/day glucocorticoids; patients not meeting these criteria were considered to have \u201chigher\u201d active disease. Data were compared between patients with low and higher disease activity. Logistic regression estimated a propensity score for SLE based on demographic and clinical characteristics. Propensity score matched analyses compared HCRU, patient-reported outcomes, income loss and treatment satisfaction in patients with low disease activity versus higher active disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 296 physicians reporting on 730 patients (46 low disease activity, 684 higher active disease), and from 377 patients\u2019 self-reported questionnaires (24 low disease activity, 353 higher active disease) were analyzed. Flaring in the previous 12 months was 2.6-fold more common among patients with higher versus low active disease. Equation\u00a05D-3\u00a0L utility index was 0.79 and 0.88 and FACIT-Fatigue scores were 34.78 and 39.79 in low versus higher active disease patients, respectively, indicating better health and less fatigue, among patients with low versus higher active disease. Absenteeism, presenteeism, overall work impairment, and total activity impairment were 47.0-, 2.0-, 2.6- and 1.5-fold greater in patients with higher versus low disease activity. In the previous 12 months there were 28% more healthcare consultations and 3.4-fold more patients hospitalized in patients with higher versus low disease activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared to SLE patients with higher active disease, patients with low disease activity experienced better health status, lower HCRU, less fatigue, and lower work productivity impairment, with work absenteeism being substantially lower in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-023-00355-6","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:16:19Z","timestamp":1717578979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient-reported outcomes and healthcare resource utilization in systemic lupus erythematosus: impact of disease activity"],"prefix":"10.1186","volume":"8","author":[{"given":"Zahi","family":"Touma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Costenbader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan S.","family":"Karyekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"11","key":"355_CR1","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1177\/0961203320941941","volume":"29","author":"A Suarez-Avellaneda","year":"2020","unstructured":"Suarez-Avellaneda A, Quintana JH, Aragon CC, Gallego LM, Gallego CN, Bolanos JD, Ochoa MAG, Granados ME, Ruiz-Ordonez M. Systemic lupus erythematosus in the intensive care unit: a systematic review. Lupus. 2020;29(11):1364\u201376.","journal-title":"Lupus"},{"issue":"1","key":"355_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0961203318817132","volume":"28","author":"K Tselios","year":"2019","unstructured":"Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114\u201322.","journal-title":"Lupus"},{"issue":"9","key":"355_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1191\/096120300672904669","volume":"9","author":"DA Isenberg","year":"2000","unstructured":"Isenberg DA, Gordon C, Group BGBILA. From BILAG to BLIPS\u2013disease activity assessment in lupus past, present and future. Lupus. 2000;9(9):651\u20134.","journal-title":"Lupus"},{"key":"355_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-015-0702-6","volume":"17","author":"J Mikdashi","year":"2015","unstructured":"Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17:183.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"355_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1191\/096120301678646146","volume":"10","author":"SC Bae","year":"2001","unstructured":"Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus. 2001;10(6):405\u20139.","journal-title":"Lupus"},{"issue":"Suppl 11","key":"355_CR6","first-page":"37","volume":"63","author":"J Romero-Diaz","year":"2011","unstructured":"Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of british Isles Lupus Assessment Group (BILAG 2004), european Consensus Lupus Activity measurements (ECLAM), systemic lupus activity measure, revised (SLAM-R), systemic lupus activity questionnaire for Population Studies (SLAQ), systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and systemic Lupus International collaborating Clinics\/American college of rheumatology damage index (SDI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):37\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"355_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630\u201340.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"355_CR8","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"issue":"1","key":"355_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0961203310385163","volume":"20","author":"Z Touma","year":"2011","unstructured":"Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20(1):67\u201370.","journal-title":"Lupus"},{"issue":"24","key":"355_CR10","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa051135","volume":"353","author":"M Petri","year":"2005","unstructured":"Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550\u20138.","journal-title":"N Engl J Med"},{"key":"355_CR11","doi-asserted-by":"crossref","unstructured":"Hammond ER, Desta B, Near AM, Wang X, Jiang M. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004\u20132015. Lupus Sci Med 2021, 8(1).","DOI":"10.1136\/lupus-2021-000504"},{"issue":"9","key":"355_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/acr.24023","volume":"72","author":"AL Yeo","year":"2020","unstructured":"Yeo AL, Koelmeyer R, Kandane-Rathnayake R, Golder V, Hoi A, Huq M, Hammond E, Nab H, Nikpour M, Morand EF. Lupus Low Disease Activity State and reduced Direct Health Care costs in patients with systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020;72(9):1289\u201395.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"355_CR13","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"355_CR14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615\u201321.","journal-title":"Ann Rheum Dis"},{"key":"355_CR15","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, Wu Y-JJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O\u2019Neill S, Goldblatt F, Lau CS, Li ZG, Hoi A, Nikpour M, Moran EF. For Asia-Pacific Lupus collaboration: Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1:e95\u2013102.","journal-title":"Lancet Rheumatol"},{"key":"355_CR16","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, Pons-Estel BA, Rahman A, Ugarte-Gil MF, Voskuyl A et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 2021, 8(1).","DOI":"10.1136\/annrheumdis-2021-eular.1192"},{"issue":"5","key":"355_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/annrheumdis-2017-212504","volume":"77","author":"EF Morand","year":"2018","unstructured":"Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018;77(5):706\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"355_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40744-016-0047-x","volume":"3","author":"A Schwarting","year":"2016","unstructured":"Schwarting A, Schroeder JO, Alexander T, Schmalzing M, Fiehn C, Specker C, Perna A, Cholmakow-Bodechtel C, Koscielny VB, Carnarius H. First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of systemic Lupus Erythematosus in Germany: results from the OBSErve Germany Study. Rheumatol Ther. 2016;3(2):271\u201390.","journal-title":"Rheumatol Ther"},{"issue":"11","key":"355_CR19","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"355_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1191\/096120399680411281","volume":"8","author":"M Petri","year":"1999","unstructured":"Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8(8):685\u201391.","journal-title":"Lupus"},{"issue":"3","key":"355_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"5","key":"355_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"issue":"5","key":"355_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/rheumatology\/36.5.551","volume":"36","author":"NP Hurst","year":"1997","unstructured":"Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36(5):551\u20139.","journal-title":"Br J Rheumatol"},{"key":"355_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/1-4020-5511-0","volume-title":"EQ-5D value sets: Inventory, comparative review and user guide","author":"A Szende","year":"2007","unstructured":"Szende A, Oppe M, Devlin N. EQ-5D value sets: Inventory, comparative review and user guide. Netherlands: Springer; 2007."},{"issue":"2","key":"355_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528\u201338.","journal-title":"Cancer"},{"issue":"2","key":"355_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63\u201374.","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"355_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0961203313476360","volume":"22","author":"M Kosinski","year":"2013","unstructured":"Kosinski M, Gajria K, Fernandes AW, Cella D. Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus. 2013;22(5):422\u201330.","journal-title":"Lupus"},{"issue":"4","key":"355_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3899\/jrheum.100799","volume":"38","author":"JS Lai","year":"2011","unstructured":"Lai JS, Beaumont JL, Ogale S, Brunetta P, Cella D. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol. 2011;38(4):672\u20139.","journal-title":"J Rheumatol"},{"key":"355_CR29","doi-asserted-by":"crossref","unstructured":"Strand V, Simon LS, Meara AS, Touma Z. Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Sci Med 2020, 7(1).","DOI":"10.1136\/lupus-2019-000373"},{"issue":"5","key":"355_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353\u201365.","journal-title":"PharmacoEconomics"},{"key":"355_CR31","unstructured":"Salary and Cost of Living Comparison [Internet]. Available from: http:\/\/www.salaryexplorer.com."},{"key":"355_CR32","unstructured":"OECD. OECD Statistics [Internet]. Available from: https:\/\/stats.oecd.org."},{"key":"355_CR33","unstructured":"Statista. The statistics portal for market data, market research and market studies [Internet]. Available from: https:\/\/www.statista.com."},{"key":"355_CR34","unstructured":"NBC. International: Top News And Analysis [Internet]. CNBC. Available from: https:\/\/www.cnbc.com."},{"key":"355_CR35","unstructured":"Deutsche Welle. News and current affairs from Germany and around the world | DW [Internet]. Available from: https:\/\/www.dw.com."},{"key":"355_CR36","unstructured":"The Local - Germany\u2019s News in English [Internet]. Available from: https:\/\/www.thelocal.de\/\/."},{"key":"355_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"P Rosenbaum","year":"1983","unstructured":"Rosenbaum P, Rubin DB. The Central Role of the Propensity score in Observational Studies for Causal Effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"issue":"25","key":"355_CR38","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"key":"355_CR39","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3982\/ECTA11293","volume":"84","author":"A Abadie","year":"2016","unstructured":"Abadie A, Imbens G. Matching on the estimated propensity score. Econometrica. 2016;84:781\u2013807.","journal-title":"Econometrica"},{"key":"355_CR40","volume-title":"Stata Statistical Software: release 16. In. College Station","author":"StataCorp","year":"2019","unstructured":"StataCorp. Stata Statistical Software: release 16. In. College Station. TX: StataCorp LLC; 2019."},{"key":"355_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/PROM.S109479","volume":"9","author":"J Mikdashi","year":"2018","unstructured":"Mikdashi J. Measuring and monitoring health-related quality of life responsiveness in systemic lupus erythematosus patients: current perspectives. Patient Relat Outcome Meas. 2018;9:339\u201343.","journal-title":"Patient Relat Outcome Meas"},{"issue":"3","key":"355_CR42","first-page":"525","volume":"28","author":"C Wang","year":"2001","unstructured":"Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rhuematol. 2001;28(3):525\u201332.","journal-title":"J Rhuematol"},{"issue":"6","key":"355_CR43","doi-asserted-by":"publisher","first-page":"e98883","DOI":"10.1371\/journal.pone.0098883","volume":"9","author":"SL Wang","year":"2014","unstructured":"Wang SL, Wu B, Zhu LA, Leng L, Bucala R, Lu LJ. Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus. PLoS ONE. 2014;9(6):e98883.","journal-title":"PLoS ONE"},{"issue":"8","key":"355_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0961203313491849","volume":"22","author":"C Bexelius","year":"2013","unstructured":"Bexelius C, Wachtmeister K, Skare P, Jonsson L, Vollenhoven R. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a swedish nationwide study based on patient reports. Lupus. 2013;22(8):793\u2013801.","journal-title":"Lupus"},{"key":"355_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12891-015-0621-3","volume":"16","author":"M Bjork","year":"2015","unstructured":"Bjork M, Dahlstrom O, Wettero J, Sjowall C. Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord. 2015;16:188.","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"355_CR46","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1177\/09612033211025614","volume":"30","author":"YIT Takase","year":"2021","unstructured":"Takase YIT, Doi H, Tsuji H, Hashimoto M, Ueno K, Inaba R, Kozuki T, Taniguchi M, Tabuchi Y, Watanabe R, Kitagori K, Akizuki S, Murakami K, Nakashima R, Yoshifuji H, Itaya T, Yamamoto W, Uozumi R, Tanaka M, Ohmura K, Morinobu A. Correlation between irreversible organ damage and the quality of life of patients with systemic lupus erythematosus: the Kyoto Lupus Cohort survey. Lupus. 2021;30(10):1577\u201385.","journal-title":"Lupus"},{"issue":"4","key":"355_CR47","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1590\/S0482-50042010000400006","volume":"50","author":"MG dos Reis","year":"2010","unstructured":"dos Reis MG, da Costa IP. Health-related quality of life in patients with systemic lupus erythematosus in Midwest Brazil. Rev Bras Reumatol. 2010;50(4):408\u201322.","journal-title":"Rev Bras Reumatol"},{"issue":"1","key":"355_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12865-017-0200-5","volume":"18","author":"B Chaigne","year":"2017","unstructured":"Chaigne B, Chizzolini C, Perneger T, Trendelenburg M, Huynh-Do U, Dayer E, Stoll T, von Kempis J, Ribi C, Swiss Systemic Lupus Erythematosus Cohort Study G. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the swiss systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol. 2017;18(1):17.","journal-title":"BMC Immunol"},{"issue":"11","key":"355_CR49","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, Lowe B, Cella D, Mehnert A, Hinz A. General Population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Value Health. 2018;21(11):1313\u201321.","journal-title":"Value Health"},{"issue":"2","key":"355_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/0961203318817826","volume":"28","author":"DR Azizoddin","year":"2019","unstructured":"Azizoddin DR, Gandhi N, Weinberg S, Sengupta M, Nicassio PM, Jolly M. Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus. 2019;28(2):163\u201373.","journal-title":"Lupus"},{"issue":"9","key":"355_CR51","first-page":"1699","volume":"32","author":"RL Jump","year":"2005","unstructured":"Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol. 2005;32(9):1699\u2013705.","journal-title":"J Rheumatol"},{"issue":"1","key":"355_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s41687-021-00298-x","volume":"5","author":"R Rendas-Baum","year":"2021","unstructured":"Rendas-Baum R, Baranwal N, Joshi AV, Park J, Kosinski M. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76). J Patient Rep Outcomes. 2021;5(1):33.","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"355_CR53","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/rheumatology\/key398","volume":"58","author":"L Arnaud","year":"2019","unstructured":"Arnaud L, Gavand PE, Voll R, Schwarting A, Maurier F, Blaison G, Magy-Bertrand N, Pennaforte JL, Peter HH, Kieffer P, et al. Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. Rheumatology (Oxford). 2019;58(6):987\u201396.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"355_CR54","first-page":"635","volume":"35","author":"EC Goligher","year":"2008","unstructured":"Goligher EC, Pouchot J, Brant R, Kherani RB, Avina-Zubieta JA, Lacaille D, Lehman AJ, Ensworth S, Kopec J, Esdaile JM, et al. Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol. 2008;35(4):635\u201342.","journal-title":"J Rheumatol"},{"issue":"6","key":"355_CR55","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/acr.22245","volume":"66","author":"C Drenkard","year":"2014","unstructured":"Drenkard C, Bao G, Dennis G, Kan HJ, Jhingran PM, Molta CT, Lim SS. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res (Hoboken). 2014;66(6):878\u201387.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"355_CR56","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1177\/0961203313498795","volume":"22","author":"C Garris","year":"2013","unstructured":"Garris C, Oglesby A, Sulcs E, Lee M. Impact of systemic lupus erythematosus on burden of illness and work productivity in the United States. Lupus. 2013;22(10):1077\u201386.","journal-title":"Lupus"},{"issue":"12","key":"355_CR57","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.24063","volume":"59","author":"P Panopalis","year":"2008","unstructured":"Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, Criswell LA, Katz P, Yelin E. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008;59(12):1788\u201395.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"355_CR58","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1177\/09612033211045063","volume":"30","author":"A Kernder","year":"2021","unstructured":"Kernder A, Dusing C, Richter J, Brinks R, Fischer-Betz R, Winkler-Rohlfing B, Aringer M, Schneider M, Chehab G. Factors detrimental to work productivity and daily activities in systemic lupus erythematosus patients - analysis of the german LuLa study. Lupus. 2021;30(12):1931\u20137.","journal-title":"Lupus"},{"issue":"14","key":"355_CR59","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/0961203319884651","volume":"28","author":"DPE Margiotta","year":"2019","unstructured":"Margiotta DPE, Fasano S, Basta F, Pierro L, Riccardi A, Navarini L, Valentini G, Afeltra A. The association between duration of remission, fatigue, depression and health-related quality of life in italian patients with systemic lupus erythematosus. Lupus. 2019;28(14):1705\u201311.","journal-title":"Lupus"},{"issue":"1","key":"355_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40273-012-0007-4","volume":"31","author":"R Meacock","year":"2013","unstructured":"Meacock R, Dale N, Harrison MJ. The humanistic and economic burden of systemic lupus erythematosus: a systematic review. PharmacoEconomics. 2013;31(1):49\u201361.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"355_CR61","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3111\/13696998.2013.802241","volume":"16","author":"H Kan","year":"2013","unstructured":"Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J Med Econ. 2013;16(6):793\u2013800.","journal-title":"J Med Econ"},{"issue":"6","key":"355_CR62","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.semarthrit.2015.11.013","volume":"45","author":"A Jonsen","year":"2016","unstructured":"Jonsen A, Hjalte F, Willim M, Carlsson KS, Sjowall C, Svenungsson E, Leonard D, Bengtsson C, Rantapaa-Dahlqvist S, Pettersson S, et al. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Semin Arthritis Rheum. 2016;45(6):684\u201390.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"355_CR63","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/1756-185X.13363","volume":"21","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Mizukami A, Kobayashi A, Ito C, Matsuki T. Disease severity and economic burden in japanese patients with systemic lupus erythematosus: a retrospective, observational study. Int J Rheum Dis. 2018;21(8):1609\u201318.","journal-title":"Int J Rheum Dis"},{"key":"355_CR64","doi-asserted-by":"publisher","first-page":"651249","DOI":"10.3389\/fmed.2021.651249","volume":"8","author":"A Gomez","year":"2021","unstructured":"Gomez A, Qiu V, Cederlund A, Borg A, Lindblom J, Emamikia S, Enman Y, Lampa J, Parodis I. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic Lupus Erythematosus. Front Med (Lausanne). 2021;8:651249.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"355_CR65","doi-asserted-by":"publisher","first-page":"103188","DOI":"10.1016\/j.autrev.2022.103188","volume":"21","author":"A Gomez","year":"2022","unstructured":"Gomez A, Parodis I. Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. Autoimmun Rev. 2022;21(11):103188.","journal-title":"Autoimmun Rev"},{"issue":"suppl1","key":"355_CR66","first-page":"i67","volume":"56","author":"MJ Lewis","year":"2017","unstructured":"Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(suppl1):i67\u2013i77.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"355_CR67","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acr.23887","volume":"72","author":"E Maningding","year":"2020","unstructured":"Maningding E, Dall\u2019Era M, Trupin L, Murphy LB, Yazdany J. Racial and ethnic differences in the prevalence and time to Onset of Manifestations of systemic Lupus Erythematosus: the California Lupus Surveillance Project. Arthritis Care Res (Hoboken). 2020;72(5):622\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"355_CR68","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/dme.12047","volume":"30","author":"C Saunders","year":"2013","unstructured":"Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S, Sattar N, Walker JJ, Wild SH, Scottish Diabetes Research Network Epidemiology G. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30(3):300\u20138.","journal-title":"Diabet Med"},{"key":"355_CR69","unstructured":"Hubbard TE, Paradis R. Real-World Evidence: A New Era for Health Care Innovation In.: The Network for Excellence in Health Innovation; 2015."},{"key":"355_CR70","unstructured":"European Pharmaceutical Market Research Association (EphMRA). : Code of Conduct September 2019, 2020(29 May)."},{"key":"355_CR71","unstructured":"US Department of Health and Human Services: Summary of the HIPAA Privacy Rule. 2003, 2020(29 May)."},{"key":"355_CR72","unstructured":"Health Information Technology (HITECH). : Health Inform Technol Act. 2009, 2020(29 May)."},{"issue":"9","key":"355_CR73","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, et al. Good publication practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","journal-title":"Ann Intern Med"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-023-00355-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-023-00355-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-023-00355-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:11:17Z","timestamp":1717582277000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-023-00355-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s41927-023-00355-6","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data collection was undertaken in line with European Pharmaceutical Marketing Research Association [] guidelines and as such it does not require ethics committee approval. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [], and Health Information Technology for Economic and Clinical Health Act legislation. []. All patients gave written informed consent before any study-related procedures were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Zahi Touma collaborated with Janssen employees on this study, has acted as a consultant for AstraZeneca, Biogen IDEC, EMD Serono, Pfizer Inc., GlaxoSmithKline, Janssen Inc., UCB, Eli Lilly and Sarkana Pharma. Karen Costenbader collaborated with Janssen employees on this study, has acted as a consultant for AstraZeneca and Neutrolis, and has research collaborations with Glaxo Smith Kline, Lilly, Exagen Diagnostics, Gilead, Amgen and Merck. Ben Hoskin, Christian Atkinson, David Bell, and James Pike are employed by Adelphi Real World. Chetan Karyekar is an employee and shareholder of Janssen pharmaceuticals. Pamela Berry is an employee and shareholder of Janssen pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}